NasdaqGS - Delayed Quote USD

United Therapeutics Corporation (UTHR)

264.27 -1.78 (-0.67%)
At close: May 10 at 4:00 PM EDT
264.27 0.00 (0.00%)
After hours: May 10 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,498,300.00
2,327,500.00
1,936,300.00
1,685,500.00
1,483,300.00
Cost of Revenue
278,100.00
257,500.00
151,600.00
122,500.00
108,100.00
Gross Profit
2,220,200.00
2,070,000.00
1,784,700.00
1,563,000.00
1,375,200.00
Operating Expense
963,400.00
885,100.00
805,000.00
1,007,100.00
781,600.00
Operating Income
1,256,800.00
1,184,900.00
979,700.00
555,900.00
593,600.00
Net Non Operating Interest Income Expense
128,500.00
103,400.00
12,800.00
-1,900.00
5,100.00
Other Income Expense
-4,300.00
-14,000.00
-41,900.00
39,900.00
40,200.00
Pretax Income
1,381,000.00
1,274,300.00
950,600.00
593,900.00
638,900.00
Tax Provision
330,500.00
289,500.00
223,300.00
118,100.00
124,100.00
Net Income Common Stockholders
1,050,500.00
984,800.00
727,300.00
475,800.00
514,800.00
Diluted NI Available to Com Stockholders
1,050,500.00
984,800.00
727,300.00
475,800.00
514,800.00
Basic EPS
22.36
21.04
15.98
10.60
11.65
Diluted EPS
21.12
19.81
15.00
10.06
11.54
Basic Average Shares
46,975.00
46,800.00
45,500.00
44,900.00
44,200.00
Diluted Average Shares
49,725.00
49,700.00
48,500.00
47,300.00
44,600.00
Total Operating Income as Reported
1,256,800.00
1,184,900.00
979,700.00
555,900.00
593,600.00
Total Expenses
1,241,500.00
1,142,600.00
956,600.00
1,129,600.00
889,700.00
Net Income from Continuing & Discontinued Operation
1,050,500.00
984,800.00
727,300.00
475,800.00
514,800.00
Normalized Income
1,050,500.00
984,800.00
728,609.00
477,640.00
522,171.00
Interest Income
187,300.00
162,700.00
45,200.00
16,700.00
28,600.00
Interest Expense
58,800.00
59,300.00
32,400.00
18,600.00
23,500.00
Net Interest Income
128,500.00
103,400.00
12,800.00
-1,900.00
5,100.00
EBIT
1,439,800.00
1,333,600.00
983,000.00
612,500.00
662,400.00
EBITDA
1,494,700.00
1,386,800.00
1,034,300.00
662,400.00
712,300.00
Reconciled Cost of Revenue
278,100.00
257,500.00
151,600.00
122,500.00
108,100.00
Reconciled Depreciation
54,900.00
53,200.00
51,300.00
49,900.00
49,900.00
Net Income from Continuing Operation Net Minority Interest
1,050,500.00
984,800.00
727,300.00
475,800.00
514,800.00
Total Unusual Items Excluding Goodwill
--
--
-1,700.00
-2,300.00
-9,100.00
Total Unusual Items
--
--
-1,700.00
-2,300.00
-9,100.00
Normalized EBITDA
1,494,700.00
1,386,800.00
1,036,000.00
664,700.00
721,400.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
-391.00
-460.00
-1,729.00
12/31/2020 - 6/17/1999

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LQDA Liquidia Corporation
12.06
-3.37%
 
MNKD MannKind Corporation
4.3200
+0.23%
 
HALO Halozyme Therapeutics, Inc.
43.15
-1.57%
 
ALNY Alnylam Pharmaceuticals, Inc.
150.47
-0.59%
 
JAZZ Jazz Pharmaceuticals plc
109.63
-3.09%
 
INCY Incyte Corporation
53.06
-0.82%
 
GMAB Genmab A/S
28.84
+0.10%
 
TECH Bio-Techne Corporation
80.91
+1.71%
 
KRYS Krystal Biotech, Inc.
154.76
-2.50%
 
BMRN BioMarin Pharmaceutical Inc.
81.03
-0.84%